scispace - formally typeset
H

Haojun Chen

Researcher at Xiamen University

Publications -  36
Citations -  756

Haojun Chen is an academic researcher from Xiamen University. The author has contributed to research in topics: PET-CT & Medicine. The author has an hindex of 10, co-authored 29 publications receiving 252 citations.

Papers
More filters
Journal ArticleDOI

Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers.

TL;DR: Gallium 68 fibroblast-activation protein inhibitor PET/CT was superior to fluorine 18 fluorodeoxyglucosePET/CT in the detection of primary and metastatic lesions in gastric, duodenal, and colorectal cancers, with higher tracer uptake in most primary and cancerous lesions.
Journal ArticleDOI

Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT

TL;DR: The findings indicate that the sensitivity of [68Ga]Ga-FAPI-04 PET/CT to correctly identify primary liver tumors and metastatic lesions is equivalent to that of CE-CT and liver MRI and its use may improve tumor staging, recurrence detection, and implementation of necessary treatment modifications.
Journal ArticleDOI

Role of [ 68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [ 18 F]-FDG PET/CT.

TL;DR: In this article, the role of positron emission tomography/computed tomography (PET/CT) compared with 18F-fluorodeoxyglucose [18F]-FDG PET/CT was explored for evaluating peritoneal carcinomatosis in patients with various types of cancer.
Journal ArticleDOI

Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy

TL;DR: This study proposed a novel therapeutic regimen that combined programmed death ligand 1 (PD-L1)-based immunotherapy with peptide-based TRT (177Lu as the radionuclide) in the murine colon cancer model and demonstrated that TRT led to an acute increase in PD-L 1 expression on T cells, and TRT in combination with αPD- L1 mAb stimulated the infiltration of CD8+ T cells.
Journal ArticleDOI

Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents

TL;DR: Conjugation of the novel add-on molecule, NMEB or DMEB, to potential tracers or therapeutic agents improved blood half-life and tumor uptake and could transform such agents into theranostic entities.